Please login to the form below

Not currently logged in
Email:
Password:

Clementia Pharmaceuticals

This page shows the latest Clementia Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Ipsen buys rare disease group Clementia in $1.3bn deal

Ipsen buys rare disease group Clementia in $1.3bn deal

Will acquire lead multiple rare disease candidate palovarotene. Ipsen is set to pay out a total of $1.3bn to buy Clementia Pharmaceuticals in a move that will significantly boost its ... The acquisition of Clementia Pharmaceuticals accelerates the

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics